Atenolol and Timolol

Stephan Rössner, Leif Weiner, Anders Westerlund, Joel Zonszein, Peter Baylor, D. S. Lawrence, J. N. Sahay, S. S. Chatterjee, George T. Griffing, Christopher E. Coakley, Simmons Lessell, James C. Melby, S. Vožeh, William H. Frishman

Research output: Contribution to journalLetter

4 Scopus citations

Abstract

To the Editor: In a recent review of two β-blockers released for clinical use in the United States (June 17 issue) Frishman discusses the use of atenolol in treating hypertension.1 One side effect not mentioned in the review is the induction of lipoprotein abnormalities during β-blockade. The general pattern in most studies seems to be an increase in the concentration of very-low-density lipoproteins and a decrease in the concentration of high-density lipoproteins during β-blockade.2 Hyperlipoproteinemia is common in patients with hypertension, and an incidence of up to 40 per cent — twice as high as in controls — has.

Original languageEnglish (US)
Pages (from-to)1343-1346
Number of pages4
JournalNew England Journal of Medicine
Volume307
Issue number21
DOIs
StatePublished - Nov 18 1982

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Atenolol and Timolol'. Together they form a unique fingerprint.

  • Cite this

    Rössner, S., Weiner, L., Westerlund, A., Zonszein, J., Baylor, P., Lawrence, D. S., Sahay, J. N., Chatterjee, S. S., Griffing, G. T., Coakley, C. E., Lessell, S., Melby, J. C., Vožeh, S., & Frishman, W. H. (1982). Atenolol and Timolol. New England Journal of Medicine, 307(21), 1343-1346. https://doi.org/10.1056/NEJM198211183072116